ADAM17 and chronic kidney disease: Recent experimental evidence reports that ADAM17 is involved in chronic kidney disease (CKD), playing a pro-inflammatory and pro-fibrotic role [73]; blocking ADAM17 activity is, in fact, fibrosis and inflammation resulted attenuated, suggesting ADAM17 as a possible new valuable therapeutic target in CKD treatment.